

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



華潤鳳凰醫療控股有限公司

China Resources Phoenix Healthcare Holdings Company Limited

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 1515)

**SUPPLEMENTAL ANNOUNCEMENT
APPOINTMENT OF INDEPENDENT NON-EXECUTIVE DIRECTOR
AND CHAIRMAN**

Reference is made to the announcement of China Resources Phoenix Healthcare Holdings Company Limited dated August 7, 2018 regarding, inter alia, the appointment of Mr. Wu Ting Yuk, Anthony as (“**Mr. Wu**”) an independent non-executive Director and the chairman of the Company with effect from August 7, 2018 (the “**Announcement**”). Unless otherwise defined, all capitalized terms used herein shall have the same meanings as defined in the Announcement.

The Company would like supplement the information on the appointment of Mr. Wu as follows:

Mr. Wu Ting Yuk, Anthony, aged 63, is a leader in the healthcare industry and has extensive management experience in medical system. Mr. Wu joined the Hong Kong Hospital Authority in 1999 and was formerly its chairman from 2004 to 2013. He is the longest-serving chairman of the Hospital Authority. He has led the team of the Hospital Authority to manage all public hospitals and public clinics in Hong Kong and implement the public health policy of the Hong Kong SAR Government. He has also actively promoted a number of public and private medical co-operation projects during his tenure. Mr. Wu is currently also the principal advisor to the State Administration of Traditional Chinese Medicine of the People’s Republic of China, a member of the Chinese Medicine Reform and Development Advisory Committee. He was a member of the State Council’s Medical Reform Leadership Advisory Committee and an advisor to the Public Policy Advisory Committee of the National Health and Family Planning Commission.

Other important public positions that Mr. Wu has served include member of the 12th and 13th Standing Committee of the Chinese People’s Political Consultative Conference National Committee, and a member of the Chief Executive’s Council of Advisers on Innovation and Strategic Development and the Task Force on Land Supply of the Hong Kong SAR, and has been award GBS and JP by the government of Hong Kong SAR.

Mr. Wu was a member of the General Committee of the Hong Kong General Chamber of Commerce from 2000-2017, served as its chairman from 2010-2012, and is currently a member of its Council. Mr. Wu was a partner of Ernst & Young (“EY”) from 1985 to 2015, and served as chairman of the EY’s Far East Region from 2000 to 2005. He is also the chief advisor to MUFG Bank, Ltd., the chairman of The China Oxford Scholarship Fund, an honorary professor of the Faculty of Medicine of the Chinese University of Hong Kong and the Peking Union Medical College Hospital, and an honorary fellow of the Hong Kong College of Community Medicine. Mr. Wu also has directorships in certain listed companies of the Main Board of the Stock Exchange: he is an independent non-executive director of Power Assets Holdings Limited (Stock Code: 006), Guangdong Investment Limited (Stock Code: 270) and China Taiping Insurance Holdings Company Limited (Stock Code: 966), and an executive director of Sincere Watch (Hong Kong) Limited (Stock Code: 444). He was also an independent non-executive director of Agricultural Bank of China Limited (Stock Code: 1288) from 2009 to 2015. He was also a director of the Fidelity Funds from 2011 to 2014.

Mr. Wu is a fellow of Hong Kong Institute of Certified Public Accounts and the Institute of Chartered Accountants in England and Wales, and the honorary chairman of the Institute of Certified Management Accountants (Australia) Hong Kong Branch.

On December 24, 2013, the Disciplinary Committee of the Hong Kong Institute of Certified Public Accountants (“HKICPA”) found Mr. Wu’s failure to observe, maintain or otherwise apply the requirements of HKICPA in preserving the “appearance” of independence by acting as an independent financial advisor on behalf of EY to a non-listed company whilst also a senior partner of EY who acted as auditors of such company in respect of the financial years ended December 31, 1995 to December 31, 1997, and is therefore a deemed auditor of that company under the Companies Ordinance, to be a professional misconduct (the “**Incident**”). Mr. Wu was ordered to pay a penalty of HK\$250,000, name removed from the register of certified public accountants for a period of two years from July 23, 2014, and together with the other respondents, were ordered to pay the costs of HK\$2 million to HKICPA.

The Incident was referred to the Institute of Chartered Accountants in England and Wales by HKICPA in 2014, and was dismissed by the Institute in 2017.

The Board believes that with Mr. Wu's extensive management experience in the healthcare industry and his social status, it will effectively promote the Company's business development, accelerate our mergers and acquisitions and further enhance the Group's leading position in the healthcare industry.

In particular, the Board is of the view that the Incident does not affect Mr. Wu's suitability to act as an independent non-executive Director and the chairman of the Company for the following reasons:

- (a) The Incident relates to an incident over 20 years ago and was in relation to the "appearance" of independence which does not impair the character and integrity of Mr. Wu. The decision by the Institute of Chartered Accountants in England and Wales, one of the oldest and most respectable accounting bodies in the world, to dismiss the case is the best endorsement;
- (b) Mr. Wu's contribution to the companies listed on the Stock Exchange, of which he currently is or has acted as a director has been widely recognized, despite the Incident; and
- (c) The perspective, skills and experience of Mr. Wu in relation to his professional career and public services that can be brought to the Board will benefit the future advancement and strategy of the Company.

Save as disclosed in the Announcement and this announcement, there is no other information that is required to be disclosed under Rules 13.51(2)(h) to 13.51(2)(v) of the Listing Rules and there are no other matters relating to the appointment of Mr. Wu that need to be brought to the attention of the Shareholders and the Stock Exchange.

By Order of the Board
China Resources Phoenix Healthcare Holdings Company Limited
CHENG Libing
Executive Director and Chief Executive Officer

Beijing, August 13, 2018

As at the date of this announcement, the Board comprises Mr. WU Ting Yuk, Anthony, Mr. KWONG Kwok Kong, Ms. Chiu Kam Hing Kathy and Mr. Lee Kar Chung Felix as independent non-executive Directors; Mr. WANG Yan as non-executive Director; Mr. SONG Qing, Mr. CHENG Libing, Mr. Han Yuewei, Ms. Ren Yuan and Ms. Fu Yanjun as executive Directors.